Similarly to antiviral vaccines now used to prevent cervical cancer (anti-HPV vaccine) or hepatocellular carcinoma (anti-hepatitis B vaccine) preventive vaccines against usually non-expressed retroviral antigens may stimulate long lasting CD8+ T lymphocytic response in an otherwise vulnerable host that could then become able to eradicate early malignancies expressing these retroviral antigens [58]. Here, CD8A is linked to cervical carcinoma.